close 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Change languageEesti
Ülevaade

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

Kodu・Aktsiate loetelu・Editas Medicine Inc
Search

Editas Medicine Inc

Suletud

SektorTervishoid

3 3.45

Osta

Hinna uuendus 4. mai 2026, 19:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.9

Max

3.08

Põhinäitajad

By Trading Economics

Sissetulek

19M

-5.6M

Müük

17M

25M

Aktsiakasum

-0.06

Kasumimarginaal

-22.715

Töötajad

87

EBITDA

17M

-5.3M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+145.52% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

11. mai 2026

Turustatistika

By TradingEconomics

Turukapital

56M

283M

Eelmine avamishind

-0.45

Eelmine sulgemishind

3

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.33 / 1.54 Toetus ja vastupanu

Editas Medicine Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. mai 2026, 22:17 UTC

Tulu

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

DJ

Loe

4. mai 2026, 23:47 UTC

Tulu

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

DJ

Loe

4. mai 2026, 23:45 UTC

Tulu

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

DJ

Loe

4. mai 2026, 23:45 UTC

Tulu

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

DJ

Loe

4. mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

DJ

Loe

4. mai 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

Regis: Jim Beyer To Be Chief Executive of Combined Company

DJ

Loe

4. mai 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

DJ

Loe

4. mai 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

DJ

Loe

4. mai 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

DJ

Loe

4. mai 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

DJ

Loe

4. mai 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Regis: Pro Forma Market Capitalization About A$10.7 Billion

DJ

Loe

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Shareholders to Own About 51% of Combined Company

DJ

Loe

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Board Unanimously Endorsed, Supported Deal

DJ

Loe

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Deal Unanimously Recommended by Vault Board

DJ

Loe

4. mai 2026, 22:39 UTC

Omandamised, ülevõtmised, äriostud

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

DJ

Loe

4. mai 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Regis Resources to Acquire All Ordinary Shares in Vault

DJ

Loe

4. mai 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Regis Resources, Vault Minerals Agree to Merger of Equals

DJ

Loe

4. mai 2026, 22:37 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

DJ

Loe

4. mai 2026, 22:26 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

DJ

Loe

4. mai 2026, 22:02 UTC

Tulu

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

DJ

Loe

4. mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

DJ

Loe

4. mai 2026, 21:52 UTC

Tulu

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

DJ

Loe

4. mai 2026, 21:50 UTC

Tulu

Westpac: Some Sectors More Affected Than Others>WBC.AU

DJ

Loe

4. mai 2026, 21:50 UTC

Tulu

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

DJ

Loe

4. mai 2026, 21:49 UTC

Tulu

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

DJ

Loe

4. mai 2026, 21:44 UTC

Tulu

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

DJ

Loe

4. mai 2026, 21:44 UTC

Tulu

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

DJ

Loe

4. mai 2026, 21:43 UTC

Tulu

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

DJ

Loe

4. mai 2026, 21:41 UTC

Tulu

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

DJ

Loe

4. mai 2026, 21:40 UTC

Tulu

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Editas Medicine Inc Prognoos

Hinnasiht

By TipRanks

145.52% tõus

12 kuu keskmine prognoos

Keskmine 7.12 USD  145.52%

Kõrge 15 USD

Madal 4 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Editas Medicine Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

4

Osta

3

Hoia

1

Müü

Põhineb 8 analüütiku instrumendi Editas Medicine Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.33 / 1.54Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Neutral Evidence

The bullish and bearish events are balanced.

Pikk perspektiiv

No Evidence

There are no events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Muud aktsiad sektorist

JNJ

Johnson and Johnson

224.16

↓-1.45%

UNH

UnitedHealth Group Inc

370.76

↑ +0.47%

TMO

Thermo Fisher Scientific Inc

462.35

↓-1.48%

ISRG

Intuitive Surgical Inc

452.39

↓-1.14%

ABT

Abbott Laboratories

87.56

↓-2.18%
help-icon Live chat